The greatest benefit was derived in patients with high PD-L1 in TC3 and IC3 (TC3 defined as PD-L1 expression on >50% of tumour cells and IC3 defined as >10% or more of tumour-infiltrating immune cells), with a HR for mOS of 0.41 (95% CI 0.27–0.64). The gene discussed is CD274; the disease is neoplasm.